Verition Fund Management
CPRX

Verition Fund Management’s Catalyst Pharmaceutical CPRX Stock Holding History

Verition Fund Management’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-53,944
Closed -$1.26M – 2528
2025
Q4 		$1.26M Buy
+53,944
New +$1.2M ﹤0.01% 1976
2025
Q3 		– Sell
-19,445
Closed -$422K – 3791
2025
Q2 		$422K Sell
19,445
-9,866
-34% -$233K ﹤0.01% 3032
2025
Q1 		$711K Sell
29,311
-46,795
-61% -$1.05M ﹤0.01% 2358
2024
Q4 		$1.59M Buy
76,106
+8,604
+13% +$185K 0.01% 1716
2024
Q3 		$1.34M Buy
67,502
+43,447
+181% +$805K 0.01% 1677
2024
Q2 		$373K Buy
+24,055
New +$374K ﹤0.01% 2222
2022
Q4 		– Sell
-10,022
Closed -$129K – 2249
2022
Q3 		$129K Buy
+10,022
New +$119K ﹤0.01% 2582
2015
Q2 		– Sell
-23,050
Closed -$100K – 632
2015
Q1 		$100K Buy
+23,050
New +$83.1K 0.01% 346

Other funds holding CPRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Verition Fund Management's CPRX Position: Q1 2026 in Review

Verition Fund Management sold out of Catalyst Pharmaceutical (CPRX) in Q1 2026, closing a stake of 53,944 shares — an estimated $1.26M sold.

Verition Fund Management first reported a position in CPRX in Q1 2015 and held it in 8 quarters. The position peaked at $1.59M in Q4 2024. 380 funds tracked by Wall St. Rank hold CPRX as of Q1 2026.

  • Verition Fund Management reported no remaining Catalyst Pharmaceutical position as of Q1 2026 after selling out during the quarter.
  • Verition Fund Management sold 53,944 Catalyst Pharmaceutical shares in Q1 2026, an estimated $1.26M.
  • Verition Fund Management first reported a position in Catalyst Pharmaceutical in Q1 2015 and held it in 8 quarters.
  • Verition Fund Management's Catalyst Pharmaceutical position peaked at $1.59M in Q4 2024.
  • 380 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q1 2026.

Based on Verition Fund Management's 13F filing for Q1 2026, filed 15 May 2026.